Scholarlink

Background <p>Data are lacking on longitudinal outcomes of patients treated in primary care–led long COVID (LC) clinics.</p> Objective <p>Assess changes in health-related quality of life (HRQoL) in patients with LC and neurocognitive symptoms from enrollment in a LC clinic to 6&#xa0;months post-enrollment.</p> Design <p>Observational cohort study.</p> Setting <p>Primary care–led LC clinic at an academic medical center.</p> Participants <p>One hundred fifty patients with long COVID and neurocognitive symptoms who completed the PROMIS29 inventory at clinic enrollment and 6&#xa0;months post-enrollment.</p> Interventions <p>Multimodality care consisting of disease education and behavioral management, rehabilitative therapies, and pharmacotherapy for LC symptoms.</p> Main Measures <p>Treatments received and change in PROMIS29 <i>t</i>-scores from enrollment to 6-month follow-up.</p> Key Results <p><i>T</i>-scores (mean, SE) at clinic entry were worse than the population mean (50) for fatigue (65.6, 1.05), sleep disturbance (57.3, 1.00), anxiety (60.0, 1.26), physical function (37.9, 0.87), social role participation (40.2, 0.84), pain (60.1, 1.24), and depression (57.3, 1.11). Patients received multimodality treatment consisting of disease education and behavioral management (all patients), combined rehabilitation and pharmacotherapy (44%), rehabilitation only (22%), or pharmacotherapy only (16%). There were statistically significant improvements in mean <i>t</i>-scores in all PROMIS29 domains at 6&#xa0;months. Clinically significant improvement (change in <i>t</i>-score of ≥ 2.5) was seen for physical functioning (+ 2.9, 0.58), fatigue (− 4.9, 0.80), social functioning (+ 3.4, 0.68), and pain (− 2.8, 0.88). Change in <i>t</i>-score &gt; 5 was seen in fatigue with symptom-titrated physical rehabilitation, in fatigue and pain with amantadine and memantine, and in sleep disturbance and pain with trazodone and amitriptyline.</p> Conclusion <p>Multimodal symptom–directed interventions incorporating rehabilitation alongside targeted pharmacotherapy were associated with significantly improved HRQoL in patients with LC and neurological symptoms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of Patients with Neurocognitive Symptoms Attending a Long COVID Clinic: A Longitudinal Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Aaron Friedberg,
  • Erin McConnell,
  • Stacy Stanwick ,
  • Leanna Perez ,
  • Sarah MacEwan,
  • Laura J. Rush ,
  • Susan Bowman-Burpee ,
  • Rachel M. Smith,
  • Shivam Joshi ,
  • Kathleen Woschkolup ,
  • Jodi Grandominico ,
  • Ann Scheck McAlearney,
  • Andrew Schamess

摘要

Background

Data are lacking on longitudinal outcomes of patients treated in primary care–led long COVID (LC) clinics.

Objective

Assess changes in health-related quality of life (HRQoL) in patients with LC and neurocognitive symptoms from enrollment in a LC clinic to 6 months post-enrollment.

Design

Observational cohort study.

Setting

Primary care–led LC clinic at an academic medical center.

Participants

One hundred fifty patients with long COVID and neurocognitive symptoms who completed the PROMIS29 inventory at clinic enrollment and 6 months post-enrollment.

Interventions

Multimodality care consisting of disease education and behavioral management, rehabilitative therapies, and pharmacotherapy for LC symptoms.

Main Measures

Treatments received and change in PROMIS29 t-scores from enrollment to 6-month follow-up.

Key Results

T-scores (mean, SE) at clinic entry were worse than the population mean (50) for fatigue (65.6, 1.05), sleep disturbance (57.3, 1.00), anxiety (60.0, 1.26), physical function (37.9, 0.87), social role participation (40.2, 0.84), pain (60.1, 1.24), and depression (57.3, 1.11). Patients received multimodality treatment consisting of disease education and behavioral management (all patients), combined rehabilitation and pharmacotherapy (44%), rehabilitation only (22%), or pharmacotherapy only (16%). There were statistically significant improvements in mean t-scores in all PROMIS29 domains at 6 months. Clinically significant improvement (change in t-score of ≥ 2.5) was seen for physical functioning (+ 2.9, 0.58), fatigue (− 4.9, 0.80), social functioning (+ 3.4, 0.68), and pain (− 2.8, 0.88). Change in t-score > 5 was seen in fatigue with symptom-titrated physical rehabilitation, in fatigue and pain with amantadine and memantine, and in sleep disturbance and pain with trazodone and amitriptyline.

Conclusion

Multimodal symptom–directed interventions incorporating rehabilitation alongside targeted pharmacotherapy were associated with significantly improved HRQoL in patients with LC and neurological symptoms.